drugset / Trial / NCT01833923
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Phase 1
Completed
35 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis.
Timeline
- Start
- 2011-05
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 5 mg | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Catequentinib | Small molecule | 16 mg | Oral |
Indications
No indication recorded.